All In Biotech

Free tool

FDA Approval Tracker

Original approvals of brand-name drugs and biologics (NDAs and BLAs) and efficacy supplements, which add a new use, population or dose. Approvals by CBER (most vaccines, blood products and cell and gene therapies) are not in Drugs@FDA and so are missing.

Last checked: Nov 20, 2026Latest source record: Sep 28, 2026Drugs@FDA last updated: Nov 18, 2026Methods & limitations

Reset

Matching approvals

25

2023 to 2026

Breakthrough

7

Accelerated

4

Priority review

13

Orphan

23

By year

NDAs and BLAs matching the filters.

  • NDA
  • BLA
View as table
YearNDABLA
202342
202460
202571
202632

25 approvals

Newest first. Hover a badge for what it means.

  • Emcitate (Tiratricol) · Rare ThyroidSep 28, 2026
    Original approval · NDA 220963NovelPriority reviewOrphanApproval letter

    To treat peripheral thyrotoxicosis in patients with MCT8 deficiency

  • Idvynso (Doravirine, Islatravir) · MsdApr 20, 2026
    Original approval · NDA 216964NovelApproval letter

    To treat HIV-1 infection (as a complete regimen) in adults to replace the current antiretroviral regimen in those who are virologically-suppressed on a stable antiretroviral regimen with no history of virologic treatment failure and no known substitutions associated with resistance to doravirine

  • Avlayah (Tividenofusp Alfa-Eknm) · Denali Therapeutics Inc.Mar 24, 2026
    Original approval · BLA 761485NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanApproval letter

    To treat certain individuals with Hunter syndrome (Mucopolysaccharidosis type II or MPS II)

  • Yuviwel (Navepegritide) · AscendisFeb 27, 2026
    Original approval · NDA 219164NovelAccelerated approvalPriority reviewOrphanApproval letter

    To increase linear growth in pediatric patients 2 years and older with achondroplasia with open epiphyses

  • Loargys (Pegzilarginase-Nbln) · Immedica Pharma AbFeb 23, 2026
    Original approval · BLA 761211NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanApproval letter

    To treat hyperarginemia in adults and pediatric patients two years and older with Arginase 1 Deficiency, in conjunction with dietary protein restriction

  • Redemplo (Plozasiran Sodium) · ArrowheadNov 18, 2025
    Original approval · NDA 219947NovelBreakthrough therapyOrphanApproval letter

    To reduce triglycerides in adults with familial chylomicronemia syndrome

  • Kygevvi (Doxecitine, Doxribtimine) · Ucb INCNov 3, 2025
    Original approval · NDA 219792NovelBreakthrough therapyPriority reviewOrphanApproval letter

    To treat thymidine kinase 2 deficiency in patients who start to show symptoms when they are 12 years old or younger

  • Forzinity (Elamipretide Hydrochloride) · Stealth BiotherapsSep 19, 2025
    Original approval · NDA 215244NovelAccelerated approvalPriority reviewOrphanApproval letter

    To improve muscle strength in patients with Barth syndrome weighing at least 30 kg

  • Dawnzera (Autoinjector) (Donidalorsen Sodium) · Ionis Pharms INCAug 21, 2025
    Original approval · NDA 219407NovelOrphanApproval letter

    To prevent attacks of hereditary angioedema

  • Sephience (Sepiapterin) · Ptc TherapJul 28, 2025
    Original approval · NDA 219666NovelOrphanApproval letter

    To treat hyperphenylalaninemia in patients with sepiapterin-responsive phenylketonuria, in conjunction with a phenylalanine-restricted diet

  • Ekterly (Sebetralstat) · KalvistaJul 3, 2025
    Original approval · NDA 219301NovelOrphanApproval letter

    To treat acute attacks of hereditary angioedema

  • Andembry (Garadacimab-Gxii) · Csl Behring LLCJun 16, 2025
    Original approval · BLA 761367NovelOrphanApproval letter

    To prevent attacks of hereditary angioedema

  • Grafapex (Treosulfan) · MedexusJan 21, 2025
    Original approval · NDA 214759NovelOrphanApproval letter

    For use in combination with fludarabine as a preparative regimen for allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia and myelodysplastic syndrome

  • Tryngolza (Autoinjector) (Olezarsen Sodium) · Ionis Pharms INCDec 19, 2024
    Original approval · NDA 218614NovelBreakthrough therapyPriority reviewOrphanApproval letter

    To treat familial chylomicronemia syndrome

  • Crenessity (Crinecerfont) · NeurocrineDec 13, 2024
    Original approval · NDA 218808NovelBreakthrough therapyPriority reviewOrphanApproval letter

    To treat classic congenital adrenal hyperplasia

  • Attruby (Acoramidis Hydrochloride) · Bridgebio PharmaNov 22, 2024
    Original approval · NDA 216540NovelOrphanApproval letter

    To treat cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis

  • Rytelo (Imetelstat Sodium) · GeronJun 6, 2024
    Original approval · NDA 217779NovelOrphanApproval letter

    To treat low- to intermediate-1 risk myelodysplastic syndromes

  • Xolremdi (Mavorixafor) · X4 PharmsApr 26, 2024
    Original approval · NDA 218709NovelPriority reviewOrphanApproval letter

    To treat WHIM syndrome (warts, hypogammaglobulinemia, infections and myelokathexis)

  • Duvyzat (Givinostat Hydrochloride) · Italfarmaco SpaMar 21, 2024
    Original approval · NDA 217865NovelPriority reviewOrphanApproval letter

    To treat Duchenne muscular dystrophy in individuals aged 6 years and older

  • Wainua (Autoinjector) (Eplontersen Sodium) · Astrazeneca AbDec 21, 2023
    Original approval · NDA 217388NovelOrphanApproval letter

    To treat polyneuropathy of hereditary transthyretin-mediated amyloidosis

  • Agamree (Vamorolone) · Catalyst PharmsOct 26, 2023
    Original approval · NDA 215239NovelOrphanApproval letter

    To treat Duchenne muscular dystrophy

  • Pombiliti (Cipaglucosidase Alfa-Atga) · Amicus Therap USSep 28, 2023
    Original approval · BLA 761204NovelBreakthrough therapyOrphanApproval letter

    To treat late-onset Pompe disease

  • Elfabrio (Pegunigalsidase Alfa-Iwxj) · Chiesi Farmaceutici SpaMay 9, 2023
    Original approval · BLA 761161NovelPriority reviewApproval letter

    To treat confirmed Fabry disease

  • Joenja (Leniolisib Phosphate) · PharmingMar 24, 2023
    Original approval · NDA 217759NovelPriority reviewOrphanApproval letter

    To treat activated phosphoinositide 3-kinase delta syndrome

  • Daybue (Trofinetide) · Acadia Pharms INCMar 10, 2023
    Original approval · NDA 217026NovelPriority reviewOrphanApproval letter

    To treat Rett syndrome

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.